The American Journal of Managed Care

Effect of Changing COPD Triple-Therapy Inhaler Combinations on COPD Symptoms

Changing patients from an inhaled corticosteroid (ICS)/long-acting β agonist (LABA) inhaler and long-acting muscarinic agonist (LAMA) inhaler to a LAMA/LABA inhaler and a separate ICS inhaler did not ...
The American Journal of Managed Care

New LAMA/LABA FDC Inhaler May Be Better Option for COPD Patients

The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use. As ...
Medscape

New Inhaled Therapies for COPD

We have had 2 long-acting ICS/LABA combinations for several years: a fluticasone/salmeterol combination (Advair®) and a formoterol/budesonide combination (Symbicort ...
FiercePharma

Despite Increasing Competition From Emerging Agents, Surveyed Pulmonologists and PCPs Will Prescribe Advair to a Higher Percenta

Surveyed MCOs Express Greater Uncertainty Regarding the Use of Boehringer Ingelheim's Combivent for COPD Than They Do for the Use of Fixed-Dose LABA/ICS Combination Inhalers, According to a New Report ...
Medscape

LABA vs LABA-ICS for COPD

For patients with moderate to severe chronic obstructive pulmonary disease (COPD), treatment options include a long-acting beta-agonist (LABA) alone or a LABA combined with an inhaled corticosteroid ...
Nature

Inappropriate prescribing of combination inhalers in Northern Ireland: retrospective cross-sectional cohort study of prescribing practice in primary care

Asthma management guidelines advocate a stepwise approach to asthma therapy, including the addition of a long-acting bronchodilator to inhaled steroid therapy at step 3. This is almost exclusively ...
EurekAlert!

Disruption in combination inhaled corticosteroid therapy may lead to an increased rate of costly exacerbations and hospitalizations for Medicare patients

Disruption of the refill of patients' regular combination inhaled corticosteroid therapy brand may have impacted symptoms and disease control and potentially lead to an increased rate of costly ...
News Medical

Disruption in combination inhaled corticosteroid therapy may impact patients' symptoms and disease control

Disruption of the refill of patients' regular combination inhaled corticosteroid therapy brand may have impacted symptoms and disease control and potentially lead to an increased rate of costly ...
Nasdaq

Novartis receives CHMP positive opinion for Enerzair® Breezhaler® (QVM149), a potential first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthma

Basel, May 1, 2020 — Novartis today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval ...
Monthly Prescribing Reference

FDA: Boxed Warning About Asthma-Related Death Removed for LABA/ICS Combos

The four trials also assessed efficacy of the ICS/LABA products. Based on a review of four clinical safety trials, the Food and Drug Administration (FDA) has concluded that medications that contain ...
Business Wire

US FDA Updates SYMBICORT Label with LABA Safety Class Revisions and Removes Boxed WARNING for Serious Asthma-Related Outcomes

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved updates to the SYMBICORT ® (budesonide ...